Business Wire

ORDRUPGAARD

2.2.2024 16:41:29 CET | Business Wire | Press release

Share
Impressionism and Its Overlooked Women: Berthe Morisot, Mary Cassatt, Marie Bracquemond, Eva Gonzalès and Marie Bashkirtseff

The 150th anniversary of the first impressionist exhibition in Paris in 1874 is celebrated at Ordrupgaard with a magnificent exhibition highlighting the women of impressionism – both behind and in front of the canvas. The exhibition features four female impressionists and their interconnected world of sisters, daughters, and friends through what is incontestably regarded as major works of this period. Due to their gender and class, these artists did not have the same opportunities to depict the pulsating city life enjoyed by their male colleagues. Instead, their focus was on modern life as it unfolded in the home and gardens of Paris and the surrounding area. These intimate motifs were depicted in a radical fashion using bright colours, quick brushstrokes, and a sketch-like technique, which elicited both admiration and indignation from viewers and art critics alike. The exhibition traces the women’s struggle for recognition and a place in art history, examining in more detail their pioneering contribution to the emergence of modern art.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240202310892/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Berthe Morisot, The Psyche Mirror, 1876. Museo Nacional Thyssen-Bornemisza. (Photo: Business Wire)

With exceptional loans from around the world, visitors will experience main works by Berthe Morisot (1841–1895) and Mary Cassatt (1844–1926), both of whom are well-known, as well as Marie Bracquemond (1840–1916), Eva Gonzalès (1849–1883), and Marie Bashkirtseff (1858–1884) who, until now, have been off the radar. Marie Bashkirtseff did not belong to the impressionists as such, but in her diary, ’Journal de Marie Bashkirtseff’, published posthumously in 1887, she described the conditions of female artists at the time.

Additionally, the exhibition features key works by Édouard Manet, Edgar Degas, and Pierre-Auguste Renoir inasmuch as they portray female models. The exhibition directs focus at several of the women overlooked by history, immortalised in several of impressionism’s most iconic paintings: from the coloured models in Manet’s and Degas’s pictures to the numerous members and friends perpetuated in the female artists’ canvases. The exhibition seeks not only to examine the technique used to paint these women but also to look at their identity, which unleashes new narratives and overlooked perspectives on impressionism and its actors.

This is the first showing of works by Bashkirtseff and Bracquemond in Denmark and, likewise, bringing together the leading artists in the exhibition is a first of its kind in Scandinavia. We show 57 paintings loaned by 34 lenders from 10 countries.

Press meeting, 9 Feb, 10–12.

https://ordrupgaard.dk/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240202310892/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye